Proactive Investors - Run By Investors For Investors

Summit Therapeutics shoots higher as data shows SMT-57 antibiotic potent against diverse, global gonorrhoeae strains

The group said SMT-571 was potent against Neisseria gonorrhoeae strains from actual patient cases, including numerous multi- and extensively-drug resistant strains
Clinical data
Importantly, Summit added, SMT-571 did not show cross-resistance with any antimicrobials currently or previously used for the treatment of gonorrhoea

Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT) shares shot higher on Monday after the group said published preclinical data showed the SMT-571 new mechanism antibiotic it is developing was found to be potent against diverse, global gonorrhoeae strains.

The AIM and Nasdaq-listed firm added that SMT-571 – which is being developed in collaboration with the Örebro University in Sweden – was potent against Neisseria gonorrhoeae strains from actual patient cases, including numerous multi- and extensively-drug resistant strains.

READ: Summit Therapeutics says first patient dosed in global Phase 3 clinical trials for its precision oral antibiotic, ridinilazole

Professor Magnus Unemo, of Örebro University, a WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, and senior author of the paper, commented: “Antibiotics with a new mechanism of action will be important in addressing the global health threat of gonorrhoea.

“In the published data, we demonstrated that SMT-571, a new mechanism antibiotic, had consistently high potency across hundreds of relevant clinical strains of N. gonorrhoeae, including those that are multi- and extensively-drug resistant. I look forward to the continued development of SMT-571.”

The paper, entitled ‘In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?,’ was published in the Journal of Antimicrobial Chemotherapy and authored by Unemo and S. Jacobsson of Örebro University, as well as C. Mason, N. Khan and P. Meo of Summit.

In the study, Summit, said, researchers tested SMT-571 against 228 clinical isolates and 34 international gonococcal reference strains. SMT-571 achieved potent activity with minimum inhibitory concentrations of 0.064 to 0.125 mg/L against all tested strains.

Importantly, it added, SMT-571 did not show cross-resistance with any antimicrobials currently or previously used for the treatment of gonorrhoea.

These data further expand the range of N. gonorrhoeae strains against which SMT-571 has shown activity, indicating SMT-571 is a promising new mechanism antibiotic in development for the treatment of gonorrhoea, Summit concluded.

In early afternoon trading in London, Summit shares were 14% higher at 24.50p, having initially jumped to 28p a share.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use